KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Depreciation and Depletion (2020 - 2024)

Aurinia Pharmaceuticals' Depreciation and Depletion history spans 5 years, with the latest figure at -$14.0 million for Q4 2024.

  • For Q4 2024, Depreciation and Depletion fell 129.3% year-over-year to -$14.0 million; the TTM value through Dec 2024 reached $600000.0, changed 0.0%, while the annual FY2025 figure was $600000.0, 0.0% changed from the prior year.
  • Depreciation and Depletion reached -$14.0 million in Q4 2024 per AUPH's latest filing, down from $4.9 million in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $5.3 million in Q3 2023 to a low of -$14.0 million in Q4 2024.
  • Average Depreciation and Depletion over 5 years is $90176.5, with a median of $687000.0 recorded in 2022.
  • Peak YoY movement for Depreciation and Depletion: skyrocketed 5633.33% in 2021, then tumbled 223.16% in 2023.
  • A 5-year view of Depreciation and Depletion shows it stood at $12000.0 in 2020, then crashed by 11491.67% to -$1.4 million in 2021, then plummeted by 38.04% to -$1.9 million in 2022, then crashed by 223.16% to -$6.1 million in 2023, then plummeted by 129.3% to -$14.0 million in 2024.
  • Per Business Quant, the three most recent readings for AUPH's Depreciation and Depletion are -$14.0 million (Q4 2024), $4.9 million (Q3 2024), and $4.8 million (Q2 2024).